Summary

Global Dry Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Dry age-related macular degeneration is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. This condition leads to gradual loss of vision, particularly in the central field of view, which is crucial for activities such as reading, driving, and recognizing faces.

The dry age-related macular degeneration market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers is the aging global population, as age is the most significant risk factor for developing dry age-related macular degeneration. With an increasing number of elderly individuals, the demand for effective treatments and diagnostic tools is on the rise. Additionally, advancements in retinal imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are enabling earlier detection and more precise monitoring of disease progression, driving market growth.

Furthermore, the growing focus on precision medicine and genetic testing is enhancing the ability to tailor treatments to individual patients, thus improving clinical outcomes. The increasing awareness of eye health and the rising adoption of preventive measures, such as lifestyle changes and regular eye screenings, are also stimulating demand. Moreover, the improvement in healthcare infrastructure in emerging markets and the availability of specialized training for ophthalmologists are fuelling the adoption of innovative AMD treatment options. The combination of these drivers is poised to continue supporting the growth of the dry AMD market.

Despite the positive growth trajectory, several challenges continue to impact the global dry age-related macular degeneration market. One of the primary challenges is the high cost of treatment and diagnostic technologies can be a significant barrier. Innovative treatments, especially in the realm of gene therapy, stem cell therapy, and advanced imaging technologies, come with high development and implementation costs. This can limit access to effective therapies in low- and middle-income regions, where healthcare infrastructure may be less developed and resources are limited.

Moreover, lack of effective treatments for the advanced stages of dry AMD. While there are interventions to manage early stages, such as nutritional supplements and lifestyle modifications, there is no cure or approved treatment that can significantly reverse the damage once it progresses to advanced dry AMD or geographic atrophy. This limitation has restricted the market potential for advanced therapies and treatment options.

As the dry age-related macular degeneration market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The increasing development of innovative treatments, such as gene therapies, retinal implants, and biologic agents targeting disease progression, is poised to provide new hope for patients. Furthermore, advancements in diagnostic technologies, including high-resolution imaging and artificial intelligence-driven tools for early detection, will allow for more precise monitoring and intervention. With the aging global population, particularly in regions with a higher prevalence of AMD, the demand for cost-effective, easy-to-administer, and efficient treatment options will continue to rise. Additionally, increased focus on the role of lifestyle modifications, such as diet and supplements, will shape prevention strategies, offering a holistic approach to managing age-related macular degeneration.

In conclusion, the global dry age-related macular degeneration market is expected to experience steady growth, driven by advancements in therapeutic interventions, heightened awareness, and a focus on early detection. As research and development in this space continue to progress, key stakeholders, including pharmaceutical companies, healthcare providers, and researchers, will play a critical role in improving treatment outcomes and patient quality of life. The market’s expansion, coupled with continued innovation, will empower patients with better management tools, reducing the long-term burden of the condition and preserving vision for millions around the world.

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. Global Dry Age-Related Macular Degeneration Markets: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology of Dry AMD
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. Global Dry Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Dry Age-Related Macular Degeneration Market, by Country
2.1.3.1.1 U.S.
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Dry Age-Related Macular Degeneration Market, by Country
2.2.3.1.1 Germany
2.2.3.1.2 U.K.
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.3 Asia Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia Pacific Dry Age-Related Macular Degeneration Market, by Country
2.3.3.1.1 Japan
3. Global Dry Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles
3.1 Key Development and Strategies
3.1.1 Mergers and Acquisitions
3.1.2 Synergistic Activities
3.1.3 Business Expansions and Funding
3.1.4 Product Launches and Approvals
3.1.5 Other Activities
3.2 Company Profiles
3.2.1 AstraZeneca
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Target Customers/End-Users
3.2.1.4 Key Personnel
3.2.1.5 Analyst View
3.2.2 Astellas Pharma
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Target Customers/End-Users
3.2.2.4 Key Personnel
3.2.2.5 Analyst View
3.2.3 Novartis AG.
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Target Customers/End-Users
3.2.3.4 Key Personnel
3.2.3.5 Analyst View
3.2.4 Apellis Pharmaceuticals
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Target Customers/End-Users
3.2.4.4 Key Personnel
3.2.4.5 Analyst View
3.2.5 Alkeus Pharmaceuticals.
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Target Customers/End-Users
3.2.5.4 Key Personnel
3.2.5.5 Analyst View
3.2.6 Belite Bio.
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Target Customers/End-Users
3.2.6.4 Key Personnel
3.2.6.5 Analyst View
3.2.7 Aviceda Therapeutics
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Target Customers/End-Users
3.2.7.4 Key Personnel
3.2.7.5 Analyst View
3.2.8 Cognition Therapeutics
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Target Customers/End-Users
3.2.8.4 Key Personnel
3.2.8.5 Analyst View
3.2.9 Annexon Biosciences
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Target Customers/End-Users
3.2.9.4 Key Personnel
3.2.9.5 Analyst View
3.2.10 Lineage Cell Therapeutics
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Target Customers/End-Users
3.2.10.4 Key Personnel
3.2.10.5 Analyst View
4. Research Methodology
List of Figures
Figure: Global Dry Age-Related Macular Degeneration Market, Market Overview
Figure: Epidemiology of Dry Age-Related Macular Degeneration
Figure: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023 and 2035
Figure: Global Dry Age-Related Macular Degeneration Market Coverage
Figure: Global Dry Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Dry Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025
List of Tables
Table: Global Dry Age-Related Macular Degeneration Market, Clinical Trial Analysis,
Table: Global Dry Age-Related Macular Degeneration Market Dynamics, Impact Analysis
Table: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035

Press Release